In addition to genetic manipulation, novel bispecific antibodies simultaneously binding Vγ9 on γδ T cells and Her2/neu (ERBB2) expressed by tumour cells have been used to increase Vγ9Vδ2 T cell antitumour cytotoxicity [89]. This evidence concerns the gene ERBB2 and neoplasm.